The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2020 | Lung Cancer: post-frontline immunotherapy
Denis Talbot, BSc, MB, BChir, MA, PhD, FRCP, University of Oxford, Oxford, UK, takes us through a study he co-authored assessing second-line real-world treatment patterns and outcomes in patients with advanced/metastatic non-small cell lung cancer treated with first-line immuno-oncology monotherapy. This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.
